MIRA Pharmaceuticals Inc. $(MIRA)$ has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug $(IND.AU)$ application for Ketamir-2, a novel oral NMDA receptor antagonist aimed at treating neuropathic pain. This regulatory approval enables MIRA to initiate U.S.-based clinical trials. Ketamir-2 has demonstrated superior efficacy to existing treatments such as gabapentin and pregabalin in preclinical studies, with a favorable safety profile and no evidence of ketamine-associated neurotoxicity. MIRA is advancing through Phase 1 trials and plans to initiate U.S. Phase 2a trials by the end of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。